ProQR Therapeutics (PRQR) Stock Forecast, Price Target & Predictions
PRQR Stock Forecast
ProQR Therapeutics stock forecast is as follows: an average price target of $3.63 (represents a 96.22% upside from PRQR’s last price of $1.85) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
PRQR Price Target
The average price target for ProQR Therapeutics (PRQR) is $3.63 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential 96.22% upside from PRQR's last price of $1.85.
PRQR Analyst Ratings
According to 5 Wall Street analysts, ProQR Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PRQR stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ProQR Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 14, 2024 | Keay Nakae | Loop Capital Markets | $2.50 | $2.32 | 7.76% | 35.14% |
| Dec 30, 2022 | Raymond James Raymond James | Raymond James | $5.00 | $3.37 | 48.37% | 170.27% |
| Dec 22, 2022 | Jennifer Kim | Cantor Fitzgerald | $5.00 | $2.70 | 85.19% | 170.27% |
| Aug 12, 2022 | Keay Nakae | Chardan Capital | $2.00 | $0.81 | 145.40% | 8.11% |
The latest ProQR Therapeutics stock forecast, released on Mar 14, 2024 by Keay Nakae from Loop Capital Markets, set a price target of $2.50, which represents a 7.76% increase from the stock price at the time of the forecast ($2.32), and a 35.14% increase from PRQR last price ($1.85).
ProQR Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.50 |
| Last Closing Price | $1.85 | $1.85 | $1.85 |
| Upside/Downside | -100.00% | -100.00% | 35.14% |
In the current month, the average price target of ProQR Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ProQR Therapeutics's last price of $1.85. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 18, 2024 | Citigroup | Neutral | Neutral | Hold |
| Nov 08, 2023 | Chardan Capital | - | Buy | Upgrade |
| Apr 07, 2023 | Citigroup | Neutral | Neutral | Hold |
| Mar 30, 2023 | JMP Securities | Market Perform | Market Outperform | Upgrade |
| Dec 23, 2022 | Raymond James | Outperform | Outperform | Hold |
| Dec 22, 2022 | Cantor Fitzgerald | - | Overweight | Upgrade |
| Dec 22, 2022 | JMP Securities | Market Perform | Market Perform | Hold |
| Aug 11, 2022 | Raymond James | - | Outperform | Upgrade |
ProQR Therapeutics's last stock rating was published by Citigroup on Apr 18, 2024. The company gave PRQR a "Neutral" rating, the same as its previous rate.
ProQR Therapeutics Financial Forecast
ProQR Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $655.00K | $822.00K | $956.00K | $1.02M | $1.23M | $239.00K | $872.00K | $243.00K | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $4.42M | $4.42M | $5.53M | $5.60M | $4.12M | $11.43M | $11.44M | $2.62M | $15.84M | $4.64M | $1.22M | $1.31M | $950.82K | $841.85K | $865.20K | $802.28K | $756.63K | $234.52K | $191.67K | $452.16K | $138.19K | $99.84K | $318.31K | $422.01K | $537.69K | $861.89K | $484.01K | $627.35K | $777.25K | $3.80M |
| High Forecast | $4.42M | $4.42M | $5.53M | $5.60M | $4.12M | $11.43M | $11.44M | $2.62M | $31.11M | $4.64M | $1.22M | $1.31M | $950.82K | $841.85K | $865.20K | $1.14M | $1.08M | $333.71K | $272.74K | $643.40K | $196.64K | $142.06K | $452.94K | $600.50K | $765.11K | $1.23M | $688.73K | $892.70K | $932.70K | $4.56M |
| Low Forecast | $4.42M | $4.42M | $5.53M | $5.60M | $4.12M | $11.43M | $11.44M | $2.62M | $568.06K | $4.64M | $1.22M | $1.31M | $950.82K | $841.85K | $865.20K | $460.52K | $434.32K | $134.62K | $110.02K | $259.55K | $79.32K | $57.31K | $182.71K | $242.24K | $308.64K | $494.74K | $277.83K | $360.11K | $621.80K | $3.04M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 | 6 | 6 | 15 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 0.86% | 1.14% | 1.18% | 1.54% | 0.32% | 3.72% | 1.27% | - | - | - | - | - | - | - | - | - | - | - |
ProQR Therapeutics's average Quarter revenue forecast for Jun 23 based on 2 analysts is $1.22M, with a low forecast of $1.22M, and a high forecast of $1.22M. PRQR's average Quarter revenue forecast represents a 85.95% increase compared to the company's last Quarter revenue of $655.00K (Mar 23).
ProQR Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 | 6 | 6 | 15 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-9.25M | $-11.40M | $-15.13M | $-16.39M | $-16.37M | $-17.65M | $-14.47M | $-15.09M | $-11.97M | $-12.51M | $-10.59M | $-3.57M | $-15.53M | $-17.96M | $-11.63M | $-11.07M | $-13.64M | $-12.51M | $-5.64M |
| Avg Forecast | $-2.65M | $-2.65M | $-3.32M | $-3.36M | $-2.47M | $-6.86M | $-6.86M | $-14.35M | $-9.50M | $-2.78M | $-730.78K | $-15.17M | $-570.49K | $-16.30M | $-519.12K | $-15.94M | $-9.83M | $-10.84M | $-11.25M | $-10.28M | $-9.81M | $-10.23M | $-3.96M | $-15.53M | $-10.53M | $-12.84M | $-12.66M | $-13.38M | $-4.23M | $-9.87M |
| High Forecast | $-2.65M | $-2.65M | $-3.32M | $-3.36M | $-2.47M | $-6.86M | $-6.86M | $-11.48M | $-340.83K | $-2.78M | $-730.78K | $-12.14M | $-570.49K | $-13.04M | $-519.12K | $-12.75M | $-7.86M | $-8.67M | $-9.00M | $-8.22M | $-7.85M | $-8.18M | $-3.17M | $-12.42M | $-8.42M | $-10.27M | $-10.13M | $-10.70M | $-3.39M | $-7.90M |
| Low Forecast | $-2.65M | $-2.65M | $-3.32M | $-3.36M | $-2.47M | $-6.86M | $-6.86M | $-17.22M | $-18.66M | $-2.78M | $-730.78K | $-18.20M | $-570.49K | $-19.55M | $-519.12K | $-19.13M | $-11.80M | $-13.00M | $-13.50M | $-12.33M | $-11.78M | $-12.27M | $-4.75M | $-18.63M | $-12.63M | $-15.41M | $-15.19M | $-16.05M | $-5.08M | $-11.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.61% | 19.98% | 0.93% | 31.57% | 1.03% | 1.80% | 1.34% | 1.34% | 1.16% | 1.28% | 1.04% | 0.90% | 1.00% | 1.71% | 0.91% | 0.87% | 1.02% | 2.96% | 0.57% |
undefined analysts predict PRQR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ProQR Therapeutics's previous annual EBITDA (undefined) of $NaN.
ProQR Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 | 6 | 6 | 15 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-7.99M | $-10.63M | $-24.38M | $-14.67M | $-14.45M | $-18.24M | $-15.05M | $-15.75M | $-12.61M | $-13.22M | $-13.18M | $-4.11M | $-16.05M | $-18.54M | $-12.14M | $-11.65M | $-14.16M | $-12.92M | $-5.96M |
| Avg Forecast | $-10.90M | $-10.10M | $-7.64M | $-6.84M | $-7.13M | $-8.93M | $-10.17M | $-13.71M | $1.38M | $-7.02M | $-9.06M | $-14.49M | $-14.97M | $-16.95M | $-17.46M | $-15.22M | $-10.15M | $-11.27M | $-11.74M | $-10.71M | $-10.36M | $-12.72M | $-5.75M | $-15.62M | $-14.46M | $-12.04M | $-12.41M | $-12.94M | $-6.72M | $-6.81M |
| High Forecast | $-10.90M | $-10.10M | $-7.64M | $-6.84M | $-7.13M | $-6.70M | $-10.17M | $-10.96M | $1.38M | $-7.02M | $-9.06M | $-11.59M | $-14.97M | $-13.56M | $-17.46M | $-12.18M | $-8.12M | $-9.02M | $-9.39M | $-8.57M | $-8.29M | $-10.17M | $-4.60M | $-12.50M | $-11.57M | $-9.64M | $-9.93M | $-10.35M | $-5.38M | $-5.45M |
| Low Forecast | $-10.90M | $-10.10M | $-7.64M | $-6.84M | $-7.13M | $-11.16M | $-10.17M | $-16.45M | $1.38M | $-7.02M | $-9.06M | $-17.38M | $-14.97M | $-20.34M | $-17.46M | $-18.26M | $-12.18M | $-13.52M | $-14.09M | $-12.86M | $-12.43M | $-15.26M | $-6.90M | $-18.75M | $-17.35M | $-14.45M | $-14.89M | $-15.53M | $-8.06M | $-8.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.71% | 1.44% | 0.84% | 0.95% | 1.80% | 1.34% | 1.34% | 1.18% | 1.28% | 1.04% | 0.71% | 1.03% | 1.28% | 1.01% | 0.94% | 1.09% | 1.92% | 0.87% |
ProQR Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRQR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ProQR Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 | 6 | 6 | 15 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $4.03M | $2.97M | $5.36M | $5.41M | $4.91M | $5.32M | $4.59M | $4.12M | $3.34M | $3.51M | $2.81M | $3.45M | $3.92M | $3.92M | $2.90M | $2.88M | $3.19M | $4.64M | $2.58M |
| Avg Forecast | $24.33M | $24.33M | $30.46M | $30.83M | $22.67M | $62.90M | $62.98M | $14.45M | $87.19M | $25.53M | $6.71M | $7.22M | $5.23M | $4.63M | $4.76M | $4.42M | $4.17M | $1.29M | $1.06M | $2.49M | $760.79K | $549.63K | $1.75M | $2.32M | $2.96M | $4.75M | $2.66M | $3.45M | $4.28M | $2.95M |
| High Forecast | $24.33M | $24.33M | $30.46M | $30.83M | $22.67M | $62.90M | $62.98M | $14.45M | $171.25M | $25.53M | $6.71M | $7.22M | $5.23M | $4.63M | $4.76M | $6.29M | $5.93M | $1.84M | $1.50M | $3.54M | $1.08M | $782.10K | $2.49M | $3.31M | $4.21M | $6.75M | $3.79M | $4.91M | $5.13M | $3.54M |
| Low Forecast | $24.33M | $24.33M | $30.46M | $30.83M | $22.67M | $62.90M | $62.98M | $14.45M | $3.13M | $25.53M | $6.71M | $7.22M | $5.23M | $4.63M | $4.76M | $2.54M | $2.39M | $741.12K | $605.70K | $1.43M | $436.70K | $315.50K | $1.01M | $1.33M | $1.70M | $2.72M | $1.53M | $1.98M | $3.42M | $2.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.56% | 0.57% | 1.16% | 1.14% | 1.11% | 1.28% | 3.56% | 3.91% | 1.34% | 4.62% | 5.11% | 1.97% | 1.69% | 1.32% | 0.61% | 1.08% | 0.92% | 1.08% | 0.87% |
ProQR Therapeutics's average Quarter SG&A projection for Jun 23 is $6.71M, based on 2 Wall Street analysts, with a range of $6.71M to $6.71M. The forecast indicates a 66.55% rise compared to PRQR last annual SG&A of $4.03M (Mar 23).
ProQR Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 | 6 | 6 | 15 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.10 | $0.75 | $-0.34 | $-0.21 | $-0.20 | $-0.26 | $-0.22 | $-0.24 | $-0.25 | $-0.26 | $-0.26 | $-0.08 | $-0.32 | $-0.39 | $-0.31 | $-0.30 | $-0.36 | $-0.33 | $-0.18 |
| Avg Forecast | $-0.13 | $-0.12 | $-0.09 | $-0.08 | $-0.09 | $-0.11 | $-0.12 | $-0.11 | $0.02 | $-0.09 | $-0.11 | $-0.12 | $-0.18 | $-0.21 | $-0.21 | $-0.24 | $-0.22 | $-0.21 | $-0.21 | $-0.24 | $-0.24 | $-0.32 | $-0.31 | $-0.35 | $-0.35 | $-0.33 | $-0.38 | $-0.36 | $-0.12 | $-0.31 |
| High Forecast | $-0.13 | $-0.12 | $-0.09 | $-0.08 | $-0.09 | $-0.08 | $-0.12 | $-0.11 | $0.02 | $-0.09 | $-0.11 | $-0.12 | $-0.18 | $-0.21 | $-0.21 | $-0.11 | $-0.10 | $-0.09 | $-0.09 | $-0.11 | $-0.11 | $-0.14 | $-0.14 | $-0.15 | $-0.16 | $-0.15 | $-0.17 | $-0.16 | $-0.09 | $-0.25 |
| Low Forecast | $-0.13 | $-0.12 | $-0.09 | $-0.08 | $-0.09 | $-0.14 | $-0.12 | $-0.11 | $0.02 | $-0.09 | $-0.11 | $-0.12 | $-0.18 | $-0.21 | $-0.21 | $-0.37 | $-0.34 | $-0.32 | $-0.33 | $-0.38 | $-0.38 | $-0.49 | $-0.49 | $-0.54 | $-0.54 | $-0.51 | $-0.59 | $-0.57 | $-0.14 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.84% | -4.09% | 1.60% | 0.98% | 0.84% | 1.18% | 1.07% | 1.13% | 1.03% | 1.07% | 0.82% | 0.25% | 0.93% | 1.12% | 0.94% | 0.78% | 0.99% | 2.82% | 0.58% |
According to 2 Wall Street analysts, ProQR Therapeutics's projected average Quarter EPS for Mar 23 is $-0.12, with a low estimate of $-0.12 and a high estimate of $-0.12. This represents a -115.60% decrease compared to PRQR previous annual EPS of $0.75 (Dec 22).
ProQR Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| WVE | Wave Life Sciences | $5.86 | $14.00 | 138.91% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $21.49 | $45.38 | 111.17% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| PRQR | ProQR Therapeutics | $1.85 | $3.63 | 96.22% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
PRQR Forecast FAQ
Is ProQR Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, ProQR Therapeutics (PRQR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of PRQR's total ratings.
What is PRQR's price target?
ProQR Therapeutics (PRQR) average price target is $3.63 with a range of $2 to $5, implying a 96.22% from its last price of $1.85. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ProQR Therapeutics stock go up soon?
According to Wall Street analysts' prediction for PRQR stock, the company can go up by 96.22% (from the last price of $1.85 to the average price target of $3.63), up by 170.27% based on the highest stock price target, and up by 8.11% based on the lowest stock price target.
Can ProQR Therapeutics stock reach $3?
PRQR's average twelve months analyst stock price target of $3.63 supports the claim that ProQR Therapeutics can reach $3 in the near future.
What are ProQR Therapeutics's analysts' financial forecasts?
ProQR Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $29.61M (high $29.61M, low $29.61M), average EBITDA is $-30.544M (high $-27.673M, low $-33.414M), average net income is $-39.93M (high $-34.956M, low $-44.903M), average SG&A $163.01M (high $163.01M, low $163.01M), and average EPS is $-0.431 (high $-0.404, low $-0.459). PRQR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $19.97M (high $19.97M, low $19.97M), average EBITDA is $-11.984M (high $-11.984M, low $-11.984M), average net income is $-35.487M (high $-35.487M, low $-35.487M), average SG&A $109.96M (high $109.96M, low $109.96M), and average EPS is $-0.435 (high $-0.435, low $-0.435).
Did the PRQR's actual financial results beat the analysts' financial forecasts?
Based on ProQR Therapeutics's last annual report (Dec 2022), the company's revenue was $4.04M, beating the average analysts forecast of $3.46M by 16.67%. Apple's EBITDA was $-59.384M, beating the average prediction of $-33.323M by 78.21%. The company's net income was $-64.891M, beating the average estimation of $-64.598M by 0.45%. Apple's SG&A was $18.65M, missing the average forecast of $19.05M by -2.09%. Lastly, the company's EPS was $-0.91, beating the average prediction of $-0.847 by 7.50%. In terms of the last quarterly report (Mar 2023), ProQR Therapeutics's revenue was $655K, missing the average analysts' forecast of $1.31M by -50.03%. The company's EBITDA was $-9.248M, missing the average prediction of $-15.171M by -39.04%. ProQR Therapeutics's net income was $-7.991M, missing the average estimation of $-14.487M by -44.84%. The company's SG&A was $4.03M, missing the average forecast of $7.22M by -44.21%. Lastly, the company's EPS was $-0.0988, missing the average prediction of $-0.117 by -15.56%